Delfi Diagnostics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Delfi Diagnostics has raised $332M total to develop blood-based cancer detection using whole-genome cfDNA fragmentation analysis and ML; clinically validated FirstLook Lung test; partnering with Hackensack Meridian Health in 2025;
About
Delfi Diagnostics is a biotechnology company founded in 2019 by Victor Velculescu and headquartered in Baltimore, Maryland, specializing in blood-based cancer detection using machine learning and whole-genome sequencing of cell-free DNA (cfDNA). The company''s AI platform analyzes genome-wide fragmentation patterns of cell-free DNA from a simple blood draw — a liquid biopsy — to detect cancer-associated signals across multiple cancer types. This approach, called DELFI (DNA Evaluation of Fragments for Early Interception), generates a large number of features across the entire genome that machine learning models synthesize into a cancer risk score.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.